With a market capitalization (market cap) of $4.09B — a measure of how much the company is worth — CRISPR Therapeutics AG ranks #1,473 among the 2,418 companies tracked, and 176th in Healthcare as of November 18, 2026. Shares trade at $42.20, up 5.10% on the day.
As of November 18, 2026 · Prices may be delayed
of 2,418 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 13, 2026. The headline market cap is from the ranking update on November 18, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 13, 2026 | $4.09B | -18.87% | $42.24 |
| 2025 | Dec 31, 2025 | $5.04B | +48.91% | $52.44 |
| 2024 | Dec 31, 2024 | $3.38B | -32.19% | $39.36 |
| 2023 | Dec 29, 2023 | $4.99B | +56.66% | $62.60 |
Ranking figure $4.09B as of November 18, 2026.
Market cap = share price × shares outstanding.
CRISPR Therapeutics AG's ranking market cap is the reported market cap from the latest ranking update, with a share price of $40.75 as of November 18, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $4.09B on November 13, 2026. See how the ranking works.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 89,925,109 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $3.66B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $40.75. The headline price of $42.20 is from the ranking update on Nov 18, 2026. These updates can differ in timing.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.31T | -1.68% |
| #19 | Johnson & Johnson JNJ | $664.04B | -1.00% |
| #23 |
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 18, 2026, CRISPR Therapeutics AG (CRSP) is worth $4.09B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, CRISPR Therapeutics AG’s book equity is about $1.92B. Market cap is the market value of the outstanding shares. As of November 18, 2026, its market cap is $4.09B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
CRISPR Therapeutics AG ranks #1,473 among the 2,418 companies tracked on MarketCapLens. In Healthcare it ranks #176 of 353.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| 2022 | Dec 30, 2022 | $3.18B | -45.50% | $40.65 |
|---|
| 2021 | Dec 31, 2021 | $5.84B | — | $75.78 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
FY 2025
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $508.92B |
| -1.58% |
| #31 | Merck & Co., Inc. MRK | $342.3B | -3.09% |
| #35 | UnitedHealth Group Incorporated UNH | $318.26B | -8.69% |
| #38 | Novartis AG NVS | $294.55B | -1.99% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #1470 | Golar LNG Limited GLNG | $4.11B | -3.97% |
| #1471 | MDU Resources Group, Inc. MDU | $4.11B | +1.88% |
| #1472 | Korn Ferry KFY | $4.1B | +0.14% |
| #1474 | Paymentus Holdings, Inc. PAY | $4.09B | -1.26% |
| #1475 | SELLAS Life Sciences Group, Inc. SLS | $4.09B | +4.44% |
| #1476 | Core Natural Resources, Inc. CNR | $4.08B | +0.17% |
CRISPR Therapeutics AG’s ranking market cap of $4.09B comes from the same snapshot as the rest of this site, as of November 18, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 89,925,109. The historical market-cap series last observed $4.09B on November 13, 2026.
Over the past year, CRISPR Therapeutics AG’s market cap is down 11.09%, using historical market-cap records rather than today’s share count applied to past prices.
CRISPR Therapeutics AG (CRSP) shares trade at $42.20, up 5.10% on the day, as of November 18, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.